Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's Operating Income?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Operating Income is 
$2.8B (1Y +9.95% )

ALXN Stock Price & Operating Income

Operating Income for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for Operating Income

chevron_right 2021 $647.0M +496x *
( +25.9% / year avg)
chevron_left 1995 -$1.3M
vertical_align_top Peak $2.8B +22.7x *
vertical_align_bottom Bottom -$126.9M
arrow_drop_up # Up Years 19 19 of 27
years up.
arrow_drop_down # Down Years 8
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -0.09x the rate relative to it's operating income over the same period.
  • If ALXN grows it's stock at the same rate as it's operating income (+25.9%/year) , it's stock price will grow +1,000% and hit $1087.84 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 19 years (0%) it's operating income were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical Operating Income Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year Operating Income YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $647 -76.5% - -
    4/1/2020 $2,758 36.4% - -
    4/1/2019 $2,022 56.6% - -
    4/1/2018 $1,290 43.7% - -
    4/1/2017 $898 85.2% - -
    4/1/2016 $485 -38.5% - -
    4/1/2015 $788 -7.0% - -
    4/1/2014 $848 51.1% - -
    4/1/2013 $561 53.2% - -
    4/1/2012 $366 73.2% - -
    4/1/2011 $211 65.0% - -
    4/1/2010 $128 58.5% - -
    4/1/2009 $80 765.2% - -
    4/1/2008 $9 -107.4% - -
    4/1/2007 $-126 6.6% - -
    4/1/2006 $-119 -4.3% - -
    4/1/2005 $-124 69.7% - -
    4/1/2004 $-73 -9.6% - -
    4/1/2003 $-81 10.3% - -
    4/1/2002 $-73 96.7% - -
    4/1/2001 $-37 39.4% - -
    4/1/2000 $-26 191.8% - -
    4/1/1999 $-9 -40.3% - -
    4/1/1998 $-15 202.0% - -
    4/1/1997 $-5 -20.3% - -
    4/1/1996 $-6 392.3% - -
    4/1/1995 $-1 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • Operating Income = Gross Profit - SG&A

    A company's earnings from its normal operations before any non-operating income and/or costs such as interest expense, taxes, and special items. Income at the operating level, which is viewed as more reliable, is often used by financial analysts rather than net income as a measure of profitability.

    For more detailed definitions, please see Investopedia.